

Respiratory Drug Delivery: Essential Theory and Practice

Stephen Newman
with contributions from
Paula Anderson, Peter Byron, Richard Dalby
and Joanne Peart

Stephen Newman, Ph.D. Scientific Consultant Nottingham United Kingdom steve.newman@physics.org

Paula Anderson, M.D.
Division of Pulmonary &
Critical Care Medicine
University of Arkansas for Medical Sciences
4301 West Markham, Slot 555
Little Rock, AR 72205

Richard Dalby, Ph.D. School of Pharmacy University of Maryland, Baltimore 20 North Pine Street Baltimore, MD 21201 Peter Byron, Ph.D. School of Pharmacy Virginia Commonwealth University 410 North 12th Street Richmond, VA 23298

Joanne Peart, Ph.D. School of Pharmacy Virginia Commonwealth University 410 North 12th Street Richmond, VA 23298





10 9 8 7 6 5 4 3 2 1

ISBN: 1-933722-26-6

Copyright © 2009 Respiratory Drug Delivery Online/VCU

All rights reserved.

This book is protected by copyright. No part of it may be reproduced, stored in a retrieval system, or transmitted in any form or by any means, electronic, mechanical, photocopying, recording, or otherwise, without written permission from the publisher. Printed in the United States of America.

Where a product trademark, registration mark, or other protected mark is made in the text, ownership of the mark remains with the lawful owner of the mark. No claim, intentional or otherwise, is made by reference to any such marks in this book, whether or not these marks are identified herein as trademarks, registration marks, or other similarly protected marks. RDD® and RDD Online® are trademarks of RDD Online, LLC and Virginia Commonwealth University (VCU).

While every effort has been made by the publishers, editors, and authors to ensure the accuracy of the information contained in this book, the publishers accept no responsibility for errors or omissions. The views expressed in this book are those of the authors and may not represent those of either RDD Online or VCU.


This book is printed on sustainable resource paper approved by the Forest Stewardship Council. The printer, Sheridan Books, Inc., is a member of the Green Press Initiative and all paper used is from SFI (Sustainable Forest Initiative) certified mills.



Respiratory Drug Delivery Online Virginia Biotechnology Research Park 800 East Leigh Street, Suite 10 Richmond, Virginia 23219 United States 804-827-1490 www.rddonline.com



Figure 5. Schematic of the structure of the alveolar wall.



The alveoli contain macrophages that may engulf deposited material by phagocytosis, and either transport it to the foot of the mucociliary escalator, or transfer it into lymph nodes. This is another important lung defense mechanism, but it probably applies more to solid particles than to soluble drug substances. The alveoli also contain esterases that may inactivate deposited drugs in ways that depend on their chemical structure. Some molecules such as nicotine are believed to pass intact through the air / blood barrier, while large peptides can undergo significant enzymatic degradation (Adjei and Gupta, 1997).

Airflow and breathing

The lungs are highly elastic, and normal (tidal) breathing by an adult involves displacement of about 500 mL of air. Deep breathing can result in the inhalation and exhalation of much larger volumes. During inhalation, the diaphragm and the intercostal muscles contract to expand the lungs. Negative pressure is created within the lungs, resulting in the inhalation of air. The normal breathing rate in adults is around 15 breaths per minute, but higher breathing rates and smaller tidal volumes occur in infants and young children. The duty cycle is the fraction of the total respiratory cycle during which someone is inhaling (Collis et al., 1990). In healthy subjects, the duty cycle is slightly less than 0.5, but may be significantly less than 0.5 in patients with some lung diseases (Nikander, 1997). A possible consequence is that some patients receiving drug from nebulizers by tidal breathing could have less time available than healthy subjects to actually inhale drug into the lungs.



Table 3. Pulmonary drug delivery: major advantages for locally acting and systemically acting drugs.

Advantages for local treatments in the lungs Drugs effective in low doses compared to oral route Low incidence of systemic side effects Rapid onset of drug action, e.g. compared to oral dose

Advantages for systemic treatments via the lungs Avoidance of injections for drugs that are not absorbed orally Rapid onset of drug action, e.g. compared to subcutaneous dose

Direct delivery to the airways leads to several important clinical advantages for locally acting drugs (Table 3). First, a relatively small dose is needed. As shown in Figure 8A, inhaled doses of 200 µg albuterol and 500 µg terbutaline by pMDI are therapeutically equivalent to oral doses of several milligrams (Gebbie, 1982). Second, the low dose, coupled with the use of relatively safe inhaled compounds, results in a low incidence of systemic side effects. For instance, inhaled corticosteroids are now accepted as first line therapy for asthma, and cause far fewer systemic side effects than oral corticosteroids (Barnes, 2008). Finally, as shown in Figure 8B, the onset of drug action when given by inhalation is relatively rapid (within minutes for inhaled bronchodilators), and this is a very valuable attribute when treating sudden wheezing attacks in asthma (Köhler and Fleischer, 2000).

Advantages of the pulmonary route for systemically acting drugs

Further advantages may result from giving drugs by the pulmonary route for systemic therapy (Table 3). Many drugs are either not absorbed from the gastrointestinal tract, or have such variable absorption, that they need to be given parenterally (often by subcutaneous injection) if they are to stand any chance of being delivered predictably to the required site in the body (Davis, 1999). The use of insulin in diabetic patients is an example of this, but some patients may be unwilling to inject themselves regularly. The pulmonary epithelium offers an injection-free portal of entry to the body for drugs that are poorly absorbed when given orally (Adjei and Gupta, 1997). The pulmonary route also has advantages for vaccine delivery. In the developing world, the need to immunize by injection is a serious limitation, which could be overcome by delivering vaccines by inhalation (Laube, 2005). These issues are discussed in more detail in Chapter 10.



DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

